EDX Medical receives support from high net worth, experienced healthcare investor

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced that the Company has received a strategic investment of £300,000 from a private investor via the placing of 2,727,272 new ordinary shares of 1p each in the Company at a price of 11p per share.

The investment in the Company at a premium of 22 % on the current market share price will be used to support the expansion of EDX Medical’s capabilities and operations.

The investor is a highly experienced healthcare investor based in Saudi Arabia and has been assisted in the Placing by Capital Plus Partners, London.

An application has been made for the Placing Shares to be admitted to trading on the AQSE Growth Market and admission is expected to become effective on October 25, 2024.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
EDX Medical Group plc

More articles like this

EDX Medical Group plc

Genetic testing in cancer risk management

Discover how genetic testing can empower you to take control of your health by understanding your inherited cancer risks and taking proactive measures with NHS-supported tests.